Bionote Expands Into Veterinary Clinical Chemistry Market

DISCLAIMER: This news article is a direct translation of the original Korean article from Korea Business TV. BioNote Inc. does not claim any right to the article or claim any ownership.The translation was completed by BioNote Inc. only for the convenience of non-Korean speaking customers and BioNote Inc. does not seek to redistribute nor acquire profit from the translation.​​Bionote, an in vitro diagnostic product manufacturer, announced on the 23rd that they will be expanding into the clinical chemisry market, which is expected to grow to 1.25 billion USD by 2026.Bionote also announced that they are in the process of applying for approval of domestic and international sale of their clinical chemistry analyzer 'Vcheck C' and that they will start the approval process by January.This new product is capable of testing up to 4 samples at once, taking only 10 minutes on average, for quantitative detection of proteins, enzymes, amylase, etc. in the patient's blood samples, in order to give the veterinarian a general idea of the health of the patient in question, without sending the samples to a lab to get tested. everything can be performed on-site using this POC Clinical Chemistry Analyzer.The Clinical Chemistry market is currently valued at 768.6 million USD, and is expected to expand up to 1.25 billion USD by 2026.Bionote's CEO, DVM Byeong-Ki Cho, stated that "Bionote will provide a total diagnostic solution in the veterinary field through our Rapid, ELISA, Fluorescent immunoassay and POC Molecular Diagnostic devices as well as our new Clinical Chemistry analyzer, further improving our position as one of the global leaders in the veterinary field"Link to original article: https://www.wowtv.co.kr/NewsCenter/News/Read?articleId=A202212230095&t=NN

• 2022.12.23
• Hits : 6,353

Bionote, Listed on KOSPI (Korea Composite Stock Price Index) as of 22nd of December

DISCLAIMER: This news article is a direct translation of the original Korean article from MTN. BioNote Inc. does not claim any right to the article or claim any ownership.The translation was completed by BioNote Inc. only for the convenience of non-Korean speaking customers and BioNote Inc. does not seek to redistribute nor acquire profit from the translation.Bionote, a veterinary diagnostics and biological raw materials company, has been listed on KOSPI, the Korea Composite Stock Price Index, as of 22nd of December.At the Listing Event held at the Korea Exchange on the 22nd, DVM Byung-Ki Cho (CEO of Bionotoe), Jae-Jun Lim (Head of Korea Exchange Securities Market Division), Young-Chae Jeong (CEO of NH Investments & Securities), Il-Moon Jeong (CEO of Korea Investments & Securities) and Nam-Ki Chae (President of Korea IR Service) was in attendance.Bionote, founded in 2003, is a affiliate company of SD Biosensor and has become one of the world's leading veterinary diagnostics and biological raw materials company representing Korea, through the accumulation of proprietary R&D and know-how.Based on the company's unique genetic recombinant antigen/antibody development technical ability and manufacturing technology, it stands out in the immunodiagnostics field. Furthermore, the company can implement all processes from raw material manufacturing to finished product manufacturing through its proprietary technologies.Bionote's KOSPI listing is expected to be a giant leap towards becoming top 3 in the world in animal diagnostics and biological raw materials field. Increased brand recognition, advantageous positionings in M&A negotiations and recruitment of talented individuals are just some of the advantages of being listed on KOSPI, through which Bionote will continue to accelerate the expansion of the company and its businessEarlier, CEO of Bionote, DVM Byung-Ki Cho, strongly emphasized that he will personally make sure to fulfill Bionote's responsibilities and obligations to its investors as well as share the fruits of corporate growth with its investors.Link to original article: https://news.mtn.co.kr/news-detail/2022122208163498203 

• 2022.12.23
• Hits : 4,786

Bionote Receives '300 Million USD Export Tower', a Commemorative Trophy from Korean MOTIE and KITA, a First for Animal Diagnostic Device Company

Bionote has received the '300 million USD Export Tower' commemorative trophy. This is the second time that Bionote has received an export achievement trophy following last year's 100 million USD export commemorative trophy and it is the first time an animal diagnostic device company has received them.Every 5th of December (Official Day of Trade), the Korean Ministry of Trade, Industry and Energy (MOTIE) and the Korean International Trade Association (KITA) holds a ceremony where they select and rewards companies that have contributed to export performance through pioneering overseas markets and creating jobs, amongst other criteria. Bionote has over 160 sales networks in over 90 countries around the world, through which Bionote exports their products such as rapid diagnostic kits, fluorescence immunoassay products (Vcheck F) and ELISA kits, amongst many others. Furthermore, Bionote has subsidiaries in key countries with large diagnostic markets such as US and China, rapidly expanding Bionote's market share.Bionote's main diagnostic device, Vcheck F, is especially well received both domestically and internationally due to its high sensitivity, achieved through the use of Europium as a fluorescence material, and its capability to quantitatively measure diverse biomarkers. Bionote also expects to grow through expansion into new markets with their Vcheck M. POC Molecular Diagnostic Device, and Vcheck C, POC Clinical Chemistry Analyzer which are planned to be launched relatively soon. 

• 2022.12.20
• Hits : 4,513